# Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer

> **NCT00416429** · PHASE3 · COMPLETED · sponsor: **Centre Leon Berard** · enrollment: 456 (estimated)

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** recombinant interferon alpha-2a
- **DRUG:** medroxyprogesterone

## Key facts

- **NCT ID:** NCT00416429
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2005-02
- **Target enrollment:** 456 (ESTIMATED)
- **Last updated:** 2012-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00416429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00416429, "Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00416429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*